Chappaqua, NY, United States of America

Edward Painter

USPTO Granted Patents = 7 

Average Co-Inventor Count = 7.0

ph-index = 3

Forward Citations = 22(Granted Patents)


Company Filing History:


Years Active: 2021-2025

Loading Chart...
7 patents (USPTO):

Title: Edward Painter: Innovator in Therapeutic Compounds

Introduction

Edward Painter is a notable inventor based in Chappaqua, NY (US). He has made significant contributions to the field of therapeutic compounds, holding a total of 7 patents. His work primarily focuses on inhibitors of the menin-MLL interaction, which has implications for treating various diseases.

Latest Patents

Among his latest patents, Edward Painter has developed compounds that inhibit the binding of menin and MLL or MLL fusion proteins. These heterocyclic compounds are designed to serve as specific inhibitors of the menin-MLL interaction. Additionally, he has disclosed pharmaceutical compositions that include these compounds. The methods of using these menin-MLL inhibitors are intended for the treatment of autoimmune diseases, heteroimmune diseases, and cancers such as lymphoma and leukemia, which are dependent on menin-MLL interaction. Another significant patent involves substituted pyridines as irreversible inhibitors of the menin-MLL interaction, further expanding the potential therapeutic applications of his research.

Career Highlights

Edward Painter is currently associated with Biomea Fusion, Inc., where he continues to innovate in the field of therapeutic agents. His work has garnered attention for its potential to address critical health challenges.

Collaborations

He collaborates with notable colleagues, including Thomas Butler and Jim Palmer, who contribute to the advancement of his research initiatives.

Conclusion

Edward Painter's innovative work in developing menin-MLL inhibitors positions him as a key figure in the field of therapeutic compounds. His contributions have the potential to significantly impact the treatment of various diseases.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…